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Patterns of oxalate metabolism in recurrent oxalate stone
formers. The concentration of oxalate in the blood (isotopic
procedure), the renal clearance of oxalate, the rate of 14C-
oxalate excretion in the urine and the intestinal absorption of
14C-oxalate were used as indexes to classify different distur-
bances of oxalate metabolism in recurrent oxalate stone formers
with hyperoxaluria. By comparison with a control group, three
major patterns of oxalate metabolism were found. The first
group had normal concentrations of blood oxalate, an increased
excretion rate of isotopic oxalate and higher oxalate clearance.
The second group had higher concentrations of blood oxalate,
decreased 14C-oxalate excretion and normal or decreased oxalate
clearance. Finally, in the third group an increased oxalate ab-
sorption rate was the main alteration.
Modalités du métabolisme de I'oxalate chez les sujets atteints de
Jithiase oxalique récidivante. La concentration sanguine d'oxalate
(méthode isotopique), Ia clearance rénale de l'oxalate, le debit
d'excretion de l'oxalate C14 dans l'urine et l'absorption intes-
tinale de l'oxalate C14 ont été utilisés comme paramètres pour la
classement des différentes perturbations du métabolisme de
i'oxalate chez les sujets hyperoxaluriques formant de facon
répétitive des calculs d'oxalate. Par comparaison avec un
groupe contrôle, trois modalités majeures du métabolisme de
l'oxalate ont été mises en evidence. La premier groupe a une
concentration sanguine normale d'oxalate, une augmentation
de l'excrétion de l'oxalate marqué et des clearances de l'oxalate
augmentées. Le second groupe a des concentrations sanguines
élevées, une excretion diminuée et des clearances normales ou
diminuées. Enfin dans le troisième groupe une augmentation de
l'absorption d'oxalate est Ia modification majeure.
Urinary oxalate derives from endogenous produc-
tion or that which is ingested [1]. Renal excretion
appears to reflect the net interplay between renal
tubular mechanisms for reabsorption and secretion
[2].
Primary hyperoxaluria is known to be due to the
increased endogenous synthesis of oxalate [3]. Distur-
bances of intestinal oxalate absorption appear to be
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associated with the performance of various surgical
procedures on the gastrointestinal tract [4]. Hyper-
oxaluria and accompanying alterations of renal oxalate
have also been described [5].
Obtaining accurate measurements of blood and
urine oxalate is a major problem [6] since determina-
tions of blood oxalate concentrations vary in accord-
ance with the method used [1]. Isotopic procedures
indicate a blood oxalate concentration of approxi-
mately 15 .tg/lOO ml [7] and preliminary data from
Hodgkinson, Wilkinson and Nordin [8] yield a figure
of 226 ml/min for renal oxalate clearance in normal
individuals.
The purpose of this paper is to compare the blood
concentration of oxalate, urinary oxalate excretion
and its renal clearance in normal individuals and a
group of patients with recurrent oxalate stone for-
mation, in which hyperoxaluria was a common
finding.
Methods
Subjects. Six apparently normal men were studied
and the results were compared with those obtained
from similar studies of 20 male oxalate stone formers.
Hyperoxaluria was not observed in the normal sub-
jects and a personal or family history of renal stone
formation was not obtained. The ages of the normal
subjects ranged from 12 to 46 years (Table 1).
The stone formers had a clinical history of recurrent
oxalate stone formation. Their ages ranged from 21 to
48 years. None of the subjects had a clinical history of
urinary tract infection or bowel disease (Table 2). In
addition to standard clinical information, the selec-
tion of patients was performed in accordance with the
findings on two series of routine tests [9]. The first
series of tests included blood determinations of
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Table 1. Control group data
Clearances,
Subject
No.
ml/minIl.73 m2
Creatinine Oxalate
Urine Blood
oxalate, oxalate,
mg/24 hours jig/JOO ml
Age,
years
1 128 245 6.9 3.2 12
2 113 208 39.8 25.6 26
3 119 173 29 18 28
4 112 190 21 10 33
5 110 186 26 11 39
6 135 222 16 7 46
Mean values were obtained as described in Methods.
Table 2. Clinical findings in patients'
Urine values,
Subject No.
Age,
years
Length of
disease,
years
mg/24 hours
Calcium Oxalate
7 42 17 206 97
8 21 4 309 89
9 43 20 223 88
10 34 7 357 85ii 28 4 202 86
12 42 13 227 84
13 36 11 311 96
14 37 15 281 74
15 28 9 210 95
16 26 6 326 78
17 40 10 224 62
18 48 22 237 63
19 29 6 320 74
20 31 5 205 69
21 43 20 222 79
22 46 21 254 71
23 29 9 329 85
24 38 10 236 66
25 35 5 308 88
26 28 8 211 99
are the mean of foura Calcium and oxalate urinary values
determinations. Subjects 7 through 14 displayed increased
oxalate clearances; subjects 15 through 20 displayed hyper-
oxalemia; subjects 21 through 24 displayed defects of absorp-
tion.
sodium, potassium, chloride, calcium, phosphate,
alkaline phosphatases, pH and bicarbonate, as well as
the 24-hour urine excretion of sodium, potassium,
calcium, phosphate and oxalate. Additionally, crea-
tinine, uric acid and phosphate clearances were also
determined. Specific determinations for urinary am-
monia and titrable acidity were performed. Standard
bacteriological methods were used to detect urinary
infection. Patients with hyperoxaluria (with or with-
out hypercalciuria) as an isolated finding were selected
for this study. In the second series of tests, hyper-
oxaluria and hypercalciuria were confirmed by at
least four determinations on samples from different
days. Urinary calcium and oxalate were measured
while the subjects were maintained on a calcium
intake of 900 mg/24 hours. Normal levels of para-
thyroid hormone were shown in those subjects with
hypercalciuria [10]. Recurrent stone formation was
defined as the antecedent passing or removal (by
surgical procedures) of renal stones (on at least three
occasions) during a minimum period of four years
(Table 2).
Urine oxalate determinations. Urinary oxalate was
determined by using both the procedure of Hodgkin-
son and Williams [11] and the following method. A
10 ml sample from the filtered 24-hour urine collection
was diluted with 20 ml of water and the pH adjusted to
7.0 with 1 M NaOH. Oxalic acid 14C (6000 counts per
minute, cpm) was added to 2 ml of the solution
which was then precipitated with 2 ml of a saturated
solution of calcium sulfate and 13.5 ml of alcohol.
The solution was then allowed to stand for 24 hours
and the supernatant removed by centrifugation at
2000 x g for ten minutes. The radioactivity contained
in the supernatant was then measured. To the precipi-
tate was added 0.5 ml of 400 mg/mi aqueous solution
of potassium bromide. The suspension was thoroughly
mixed and dried at 100°C for four hours. The solid
residue was pressed down to yield a 1 x 25 mm disc.
The infrared bending at 1630 and stretching at 1310
cm' [12] were then taken. Radioactivity in the
supernatant and the disc was measured as will be
described. Similarly, a standard curve (in which
radiooxalate was added) was made up. The radio-
isotope was prepared and immediately added to the
samples. Duplicate determinations of each sample
were performed by both methods.
No radiooxalate was added to the samples to be
determined by the colorimetric procedure.
The colorimetric method was used only as a check
on the infrared procedure because it occasionally gave
erratic results.
Aliquots of 50 ml were run in each urine sample and
1 tmole of carrier oxalate was added per milliliter [7].
An average recovery of 94% was found for the infra-
red method, while the variability of recovery for the
colorimetric procedure (52 to 76%) was much higher.
However, 1.3 times higher values were obtained with
the infrared method. It is quite important to account
in each step for the appropriate corrections of the re-
covered number of counts. The urinary oxalate calcu-
lations (in these studies) were performed with the
infrared method. Nevertheless, the infrared procedure
still has a 4.9% overall error. Infrared urinary oxalate
determinations were performed, after the isotopic
clearances were run in the same manner, but without
the addition of 14C-oxalate.
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Blood oxalate concentrations. Blood oxalic acid con-
centrations were determined using the equation
described by Hodgkinson et a! [81:
Plasma oxalate concentration
cpm as 14C-oxalic blood concentration
x urine oxalic acid concentration
cpm as '4C-oxalic urine concentration
Oxalic acid-'4C was given to the subjects as described
in the following.
Oxalate excretion and clearance. Oxalate excretion
and clearance determinations were performed on
individuals in the fasting state. Enough water was
given orally to maintain an approximate urinary out-
put of 3 ml/min. Those individuals unable to maintain
this rate of urine flow were considered to be unsuitable
for the test. Changes in urinary flow from 0.5 to
3 ml/min were associated with variations in the oxalate
clearance, while higher void volumes were not accom-
panied by such variability (Table 3). Urine and blood
baseline samples were taken, and 4 Ci of '4C-oxalic
acid (u) (99% radiochemically pure) dissolved in 10 ml
of 0.9% sodium chloride was then given intra-
venously. Blood samples were taken at 30 and 90
minutes while the urine was collected at 60, 120 and
180 minutes. Additionally, the urine was collected for
48 hours, in separate periods of 6 hours. Oxalate
concentration was determined in the urine samples
obtained at 60 and 120 minutes. Radioactivity was
measured in all samples. Identification of the radio-
oxalate was made on ion exchange columns [13] and
was followed by paper chromatography on the system
just described.
Oxalate absorption. The oxalate absorption test was
carried out five days after the end of the oxalate excre-
tion and clearance determinations. Sodium oxalate
(250 mg) and 14C-oxalic acid (4 PCi) were admini-
Table 3. Typical experiment of the effect of the urinary flow on
the oxalate clearancea
Clearance,
Time,
minutes
ml/min/1.73 m2 Urine
utput volume,
mi/mm
Oxalate/
creatinine
clearance
ratio
o
Creatinine Oxalate
30 119 120 0.50 1.0
60 110 105 0.85 0.9
90 126 125 1.10 0.9
120 132 110 1.80 0.8
150 145 150 2.23 1.0
180 134 140 2.81 1.0
210 136 190 3.25 1.3
270 148 210 5.60 1.4
300 146 208 7.45 1.3
a Data were obtained on subject 5 as described in Methods.
stered orally to fasted subjects. Blood samples were
taken 1, 2, 3, 6 and 24 hours after administration of
the oxalate dose. In addition, the urine was collected
for two days in periods of 24 hours.
Measurements of radioactivity. Three milliliters of
serum from the different blood samples were precipi-
tated with 10 ml of 5% 2,5-diphenyl-oxazole (PPO)
and 0.05°,/ 1.4 bis (2-(5-phenyloxazolyl) benzene
(POPOP) in Dioxan. After centrifugation, the
supernatant was poured in the scintillation vial and
5 ml of the same solution was additionally added.
About 98% of the radioactivity was found in the super-
natant, as shown by the addition of 100 x 10 cpm of
'4C-oxalate to baseline samples. For the urine deter-
mination, 1 ml was mixed with 15 ml of the same
solution. Blanks were prepared the same way but
using the baseline samples (blood and urine).
Alternatively, the Dioxan counting solution was
replaced by PCS solution (solubilizer-phase combining
system for liquid scintillation counting of radioactive
samples, Amersham/Searle, sheet KP/ld, 11/1/71) and
determinations were performed on samples of the
same volume. No major differences between the
findings of the systems were found. The scintillation
counter was automatically set to 10,000 counts or ten
minutes. The samples were counted five times,
through a period of one week. Sample quenching was
corrected by using an internal standard. The efficiency
for the 14C was 87.5%.
Effect of urine flow on oxalate clearances in
control subjects. Urine samples were obtained by
voiding every 30 minutes, for a period of five hours.
Blood samples were taken at the midpoint of each
30-minute period. At zero time, 4 tCi of '4C-oxalate
was injected as previously described. Then, 0.9%
sodium chloride, containing 0.05 Ci/ml of '4C-
oxalate was infused intravenously at a constant rate of
0.3 mI/mm. After the first 30-minute period, increasing
volumes of water (0.7 to 4 ml/min) were delivered
dropwise by mouth. Only three of the five control
subjects, on whom this experiment was carried out, were
able to keep increasing their void volumes linearly.
The number of cpm ('4C) was used for the calculation
of oxalate clearances. Blood and urine oxalate con-
centrations were determined in all the samples.
Miscellaneous determinations. Creatinine clearances
were determined according to the procedure of Henry
[14]. Urinary calcium determinations were carried out
with Calcein [15]. The renal stone composition (in all
the patients) was analyzed by infrared absorption and
crystallographic combined procedures.
Reagents and apparatuses. The '4C-oxalic acid (u)
used for urine and blood determinations had a specific
activity of 46 mCi/mmole and was 99% radiochemi-
288 Pinto et a!
cally pure as shown in monthly testing by paper
chromatography in ethyl formate: water: formic acid
(2:1:1), PPO and POPOP. Other drugs and general
reagents used in this study included the following:
PCS; sodium iodide 125J in NaOH solution, pH 8—11
and specific activity, 100 mCi (Radiochemical Centre,
Amersham, England); highly purified bovine para-
thyroid hormone and its cross-reactive antibody of
1: 10,000 titer (Wilson Laboratories, U.S.A.); spectro-
scopy grade potassium bromide and chromotropic
acid; and calcium sulfate, potassium oxalate and
sodium oxalate (Merck & Co., Darmstadt, West
Germany). The remaining reagents were of the highest
purity available commercially. Infrared spectra were
performed on an infrared spectrophotometer (Perkin
Elmer, 700 or 377). Spectrophotometric readings in
the visible and UV range were taken on a spectro-
photometer (Hitachi Perkin Elmer, 139 Vis-U.V.);
radioactivity was measured on a liquid scintillation
counter (Nuclear Chicago, Isocap-300). The pH
readings were taken on an expanded-scale pH meter
(Crison). Infusions were maintained at a constant rate
by means of a peristaltic pump (Buchier).
Results
Determinations of serum concentration, clearance
and absorption of oxalate were performed twice on
each subject. Therefore, blood oxalate concentrations
and clearances are presented as the mean values of
four determinations. The data were analyzed by using
three indexes for each value: range of single deter-
minations, mean values on each subject and overall
mean values for the group.
Three major groups of alterations were found, in
addition to the control group.
Control group. This group consisted of six indivi-
duals whose ages ranged from 12 to 46 years (Table 1).
The single determinations of blood oxalate concentra-
tion ranged from 3 to 26 g/l00 ml (Table 4) while the
mean concentration for each subject varied from
3.2 to 25.6 g/l00 ml (Table 1). Oxalate clearance
determinations varied from 170 to 250 ml/min (Table
5) while the mean range for each subject was slightly
narrower (245 to 173 mI/mm, Table 1); the overall
mean value was 203 mI/mm (Table 4). A 24-hour
urine oxalate excretion of 40 mg was the upper normal
value. The profile of the absorption curve is shown in
Fig. 1. Of the orally administered radioactivity, 8%
was recovered in the urine (Table 5).
Patients with increased oxalate clearance. An increase
in oxalate clearance (Table 4) was the major finding in
the eight patients who comprised the largest group
studied (40% of subjects). The range for single deter-
minations, mean values for each subject and mean
values for the group are, respectively: 380 to 615
Table 4. Oxalate metabolism data
Group Subjects, Blood oxalate, Oxalate clearance Oxalate/ Absorption curve
N /Lg/100 ml ml/min/1.73 m2 creatinine
clearance
Range Mean Range Mean ratio
initial Broad
peak curve
Control 6 3—26 12.5 170—250 203 1.7 — —
Clearance increased 8 11—28 20.7 615—380 562 4.6 —
Hyperoxalemia 6 36—620 123.5 95—210 156 1.4
Defect(s) of absorption 4 16—28 26.2 180—270 240 2.0 3
Additional patients 2 73—91 — 360—470 — 3.2—3.9 1 —
Table 5. Urinary radiooxalate recovered after the absorption tests
Control group Defects of absorption group,
Type of absorption curve
Initial peak, Broad curve,
Subjects, Oxalate recovered Subjects, Oxalate recovered Subjects,
N N N
24 48 24 48
Oxalate recovered
24 48
hours, hours, hours, hours, hours, hours,0 0 0
°A °/
6 6.2 1.8 3 8.3 4.1 1 6.7 6.1
The percentage of recovered oxalate was determined as described in Methods. The data are mean values.
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Fig. 1. Typical absorption curves of the control group () and
the group with absorption disturbances (0). The rate of appear-
ance of 14C-oxalate in the blood is plotted against time. Note
that two types of curves are found in the group with absorption
disturbances.
Hours
Patient
No. 1st 2nd 6th 12th 24th 48th
7 6.3 3.9 1.2 0.1 0.1 0.07
8 7.8 3.2 1.5 0.1 0.1 0.08
9 7.5 2.9 1.2 0.3 0.3 0.04
10 6.9 3.2 1.5 0.2 0.1 0.05ii 5.9 3.7 1.8 0.2 0.2 0.09
12 7.4 2.9 1.0 0.2 0.3 0.02
13 6.8 3.1 1.2 0.2 0.2 0.06
14 5.9 3.4 1.2 0.4 0.2 0.10
15 3.2 2.3 2.1 1.7 1.0 0.20
16 2.9 2.1 2.0 1.8 1.4 0.30
17 3.9 2.4 2.2 1.6 0.8 0.05
18 3.6 2.1 1.9 1.2 0.9 0.20
19 4.1 2.5 1.8 1.3 0.7 0.10
20 4.0 2.4 1.6 1.4 0.6 0.07
21 4.7 2.4 1.8 0.7 0.6 0.08
22 5.0 2.1 1.7 0.7 0.4 0.06
23 4.6 2.0 1.7 0.8 0.5 0.05
24 4.3 2.1 1.5 0.7 0.4 0.09
25 5.0 2.6 1.4 0.6 0.2 0.10
26 5.2 2.0 1.2 0.5 0.1 0.07
The absolute amount of counts per minute x 106 as '4C-
oxalate was determined as described in Methods. Patients 7
through 14 displayed increased oxalate clearances; patients 15
through 20 displayed hyperoxalemia; patients 21 through 24
displayed absorption defects.
Clearances
Subject
No.
ml/min/1.73 m2 Blood
oxalate,
jag/100 mlCreatinine Oxalate
7 130 560 24.5
15.18 103 593
9 135 607 18.1
10 118 580 23.2
11 109 496 24.9
12 136 610 16.7
13 123 600 19.2
14 126 420 24.1
15 122 124 138.2
16 113 99 401
17 105 166 71.3
18 123 155 50.2
19 103 190 38
20 105 200 42.3
21 104 264 27.5
22 138 255 23.2
23 123 245 27.5
24 115 206 26.6
25 113 360 91
26 120 470 73
a Each value is the average of four determinations. Subjects
7 through 14 displayed increased oxalate clearances;
subjects 15 through 20 displayed hyperoxalernia; subjects
21 through 24 displayed absorption defects.
Table 7. Radiooxalate recovered in the urinea
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Table 6. Mean values of blood oxalate and clearancesa
mi/mm (Table 4), 420 to 610 mi/mm (Table 6) and
562 mi/mm (Table 4). The average blood oxalate con-
centration of 20.7 g/l00 ml (Tables 4 and 6) is
within the upper limits of normal. Radioactivity was
excreted in the urine at a faster rate (Table 7) than in
members of the control group (Fig. 2). Findings of
absorption studies were not significantly different
from those in the control group.
Patients with hyperoxalemia. Hyperoxalemia was
present in 30% of the subjects. Blood oxalate concen-
trations ranged from 36 to 620 sg/100 ml in isolated
determinations, 38 to 401 as mean values for each
subject, with a mean figure for the group of 123.5
zg/ 100 ml (Tables 4 and 6). The average oxalate clear-
ance for the group was decreased (156 ml/min), as
compared to that of the controls (Table 4). Urinary
excretion of '4C-oxalate in the 48-hour period occurred
at a slower rate (Table 7 and Fig. 2). No major
differences in results of absorption studies were found,
as compared to control group findings.
Patients with absorption defects. Absorption defects
were the third most common finding in four patients
(20% of subjects). Blood oxalate concentrations in
each subject varied from 23.2 to 27.5 g/l00 ml (16
to 28 g in single determinations) while the mean
value for the group was 26.2 g/100m1(Tables4and6).
The average oxalate clearance was slightly increased
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(Table 4). The most significant finding in this group
was the profile of the appearance of radioactivity in
the blood after oral administration of oxalate. Two
distinct profile curves were found: in one there was an
outburst of radioactivity in the blood within the first
hour; in the other type of profile, radioactivity ap-
peared in the blood gradually. This type of curve was
less frequent (one patient out of four) (Fig. 1). A net
higher increase of radioactivity was found in the
urine after the oral oxalate test (Table 5).
Additional patients. There were two subjects who
did not appear to fit into any of the three previous
groups. They exhibited various abnormalities (Tables
4 and 6) such as hyperoxalemia, and one displayed
increased oxalate absorption. Nevertheless, the urinary
excretion of radioactivity seemed to be no different
from that of the control group.
Miscellaneous findings. Changes in urine flow from
0.5 to 3 mi/mm influenced both the oxalate clearance
value (Table 3) and the oxalate-creatinine clearance
ratio. Blood oxalate concentrations were maintained
within the normal range while the effect of urine flow
on oxalate clearance was evaluated.
A discrepancy was found between the real oxalate
determined in the urine and the values calculated from
the clearance x blood product (Fig. 3).
Discussion
The present data suggest that three major patterns of
oxalate metabolism may exist in recurrent oxalate
stone formers with hyperoxaluria.
In the largest group, the main alteration was reflec-
ted by an increase in the renal clearance of oxalate.
Though firm statements cannot be made, such a
200
120
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40 80 120 160 200 240 300 500 700 900
Theoretical oxalate excretion, mg/24 hours
Fig. 3. Discrepancy between oxalate excretion values calculated
theoretically and actual mean values of urine oxalate in control
(.), clearance increased (0), hyperoxalemia () and ab-
sorption disturbances (.) groups and additional (0) patients.
Both blood oxalate concentrations and clearances were cal-
culated.
finding could be explained by an intrinsic alteration in
the renal tubular reabsorptive or secretory mechanisms
for oxalate. In the second group, hyperoxalemia and
the slight decrease of oxalate clearance were associated
with a slower excretion rate of radioactive oxalate.
This spectrum of alterations could be explained by a
decrease in oxalate clearance or an increase in the
endogenous rate of oxalate synthesis, or a combination
of the two. Whether the metabolic defects in this group
and those with primary hyperoxaluria are the same or
different has not been determined.
In the third group the altered and distinct profile of
the appearance of '4C in the blood, and the net increase
of radiooxalate excretion after the absorption test,
appear to be the major alterations. Such findings
imply that a defect of oxalate absorption may exist,
perhaps because of the existence of altered biliary com-
position [l6 orincreased activity of the intestinaltrans-
port mechanism. The mean (8% per 48 hours, 6.6%
per 24 hours) urinary recovery in the control group of
orally administered radiooxalate is in contradiction
with the 28% recovery obtained by Chadwick et al
[17] in their control group. However, there are
striking differences between their procedure and our
own. While Chadwick et al administered 10 sCi of
'4C-labeled oxalic acid together with 8 mg of nonisoto-
pic sodium oxalate, the doses we administered were
4 Ci and 250 mg, respectively. Our findings are
closer to those of previous nonisotopic studies that
report a 2.3 to 4.5% per 24 hours urinary excretion of
the oxalate intake [18]. All these observations suggest
the possible existence of an intestinal threshold for
oxalate that was perhaps exceeded in our subjects.
a
i
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Fig. 2. Urinary excretion rates of '4C-oxalate in a 48-hour period
collected at 1, 2 and 3 hours and afterward in a 6-hour period. The
total amount of 14C excreted in the 48-hour period is designated
as 100%; values of the control (•) group are compared with
those of the hyperoxalemia (0) and the increased oxalate
clearance (.)groups.
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The presence of hypercalciuria in some of the sub-
jects raises a question as to the possible relationship
between hypercalciuria and hyperoxaluria. The con-
dition does not seem to be an effect of dietary calcium
intake since the oxalate determinations were carried
out under a known calcium intake. The relationship
does not appear to be due to primary bone disease or to
a disturbance of the parathyroid glands. Though no
conclusive evidence is given, a simultaneous alteration
of calcium and oxalate metabolism seems to be related
to the hyperoxaluria through the tremendous affinity
of oxalic acid for calcium ions.
The existing discrepancies between the 24-hour urine
oxalate excretion and that theoretically calcula-
ted may be linked to the effect of urine flow (bet-
ween 0.5 and 3 mI/mm) on clearance. This suggests the
possibility that the kidney's oxalate absorption-secre-
tion mechanism is affected by rate of glomerular filtra-
tion and, perhaps, the oxalate concentration within the
tubule lumen.
Our present methods produce findings which are in
agreement with the normal values of blood oxalate
concentration and oxalate clearance reported by other
authors [8]. The apparent correlation between age and
blood oxalate concentrations in the control group
should be investigated in a larger population.
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